The very mention of the name Neurontin must cause grimaces in the legal department at Pfizer.
One week after the company was hit with a $141 million RICO verdict for falsely marketing the epilepsy drug to Kaiser for off-label uses, Pfizer agreed to settle a products liability case blaming Neurontin for contributing to a user’s suicide. Though the amount of the payment is confidential, the settlement marks the first time Pfizer has agreed to pay out on a Neurontin suicide claim.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
